tirzepatide and glaucoma Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Diabetes: Tirzepatide May Lower Risk

Both companies are expanding production and clinical trials to solidify their positions, as on December 6, 2024, the European Commission approved Novo Holdings acquisition of Catalent and related manufacturing sites for weight-loss drug production

45 (Suppl 1): S244S253

However, its important to note that while these injections are suitable for most people, they are most effective when part of a broader weight management plan that includes adopting a healthy lifestyle and behavioral changes and regular medical supervision

This next frontier of obesity drug development stems in large part from the work of Matthias Tschp and Richard DiMarchi